Ohio is currently home to 3180 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226
Recruiting
This (DEEp OLE Study) is a multicentre, open-label study to investigate the long-term safety, efficacy, tolerability, and pharmacokinetics (PK) of LP352 in the treatment of seizures in children and adults with DEE who completed Study LP352-301 or LP352-302. The study consists of 3 main phases: Screening, Titration period and Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 14 months.
Gender:
ALL
Ages:
Between 2 years and 66 years
Trial Updated:
04/09/2025
Locations: Site Number - USA14, Cincinnati, Ohio
Conditions: Developmental and Epileptic Encephalopathy
Register for Updates
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
NCT06897202
Recruiting
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2025
Locations: Research Site 097202-001010, Cincinnati, Ohio
Conditions: Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Register for Updates
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/09/2025
Locations: Velocity Clinical Research - Cincinnati, Blue Ash, Ohio
Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Register for Updates
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839
Recruiting
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/09/2025
Locations: Clinical Trial Investigator Clinical Research Center, Cincinnati, Ohio
Conditions: Obesity
Register for Updates
DG1 Spectacle Lens for Myopia Progression Control in Children
NCT06781931
Recruiting
The goal of this clinical trial is to evaluate the safety and efficacy of the DG1 spectacle lens for myopia progression control in children. * To assess if the DG1 lens will slow the progression of myopia through an adjusted mean difference (e.g., age and baseline SER) of approximately 0.75D in cycloplegic spherical equivalent autorefraction refractive error compared to single-vision (SV) spectacles over the study period. * To assess if DG1 lens will slow the progression of myopia through an ad... Read More
Gender:
ALL
Ages:
Between 7 years and 10 years
Trial Updated:
04/09/2025
Locations: ProCare Vision Centers, Inc., Granville, Ohio
Conditions: Myopia
Register for Updates
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485
Recruiting
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Local Institution - 0056, Columbus, Ohio
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141
Recruiting
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
04/09/2025
Locations: Site Number - USA14, Cincinnati, Ohio
Conditions: Developmental and Epileptic Encephalopathy
Register for Updates
A U.S. Registry of Eosinophilic Esophagitis Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
NCT06693531
Recruiting
This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/09/2025
Locations: Great Lakes Gastroenterology Research, LLC, Mentor, Ohio
Conditions: Eosinophilic Esophagitis (EoE)
Register for Updates
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
NCT06677060
Recruiting
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screening period to facilitate sites' identification of potentially eligible participants to enter the full screening assessments. Participants will not be required to visit the site and no informed consent i... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/09/2025
Locations: Research Site, Beavercreek, Ohio
Conditions: Heart Failure
Register for Updates
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
Recruiting
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
04/09/2025
Locations: Site Number - USA14, Cincinnati, Ohio
Conditions: Dravet Syndrome
Register for Updates
Esprit BTK Post-Approval Study
NCT06656364
Recruiting
The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximate... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Christ Hospital, Cincinnati, Ohio
Conditions: Chronic Limb-Threatening Ischemia
Register for Updates
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/09/2025
Locations: Velocity Clinical Research - Cleveland, Beachwood, Ohio
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates